Diagnostic accuracy of faecal biomarkers in detecting colorectal cancer and adenoma in symptomatic patients

Alimentary Pharmacology and Therapeutics

Volumn 45, Issue 2, 2017, Pages 354-363

  Widlak, M M ^a,b   Thomas, C L ^a   Thomas, M G ^c   Tomkins, C ^a   Smith, S ^a   O'Connell, N ^a   Wurie, S ^a   Burns, L ^a   Harmston, C ^a   Evans, C ^a   Nwokolo, C U ^a   Singh, B ^d   Arasaradnam, R P ^a,b,e  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^e Faculty of Engineering and Computing   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN; HEMOGLOBIN; TUMOR MARKER;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER LOCALIZATION; CLINICAL ARTICLE; COLORECTAL ADENOMA; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DYSPLASIA; FECES ANALYSIS; FEMALE; HUMAN; LIMIT OF DETECTION; MALE; MIDDLE AGED; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; VERY ELDERLY; ADENOMA; CHEMISTRY; COLORECTAL NEOPLASMS; EARLY CANCER DIAGNOSIS; FECES; IMMUNOASSAY; MASS SCREENING; METABOLISM; PROCEDURES;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FECES; FEMALE; HEMOGLOBINS; HUMANS; IMMUNOASSAY; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MASS SCREENING; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

EID: 85002165466     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13865     Document Type: Article

References (19)

1. Cancer Research UK. Bowel Cancer Statistics. Available at: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer-heading-Zero, 2015 (accessed September 2015).
2. Hewitson P, Woodrow C, Austoker J (NHS Bowel Cancer Screening Programme). Evidence Summary: Patient Information. November 2008. Available at: http://www.cancerscreening.nhs.uk/bowel/publications/nhsbcsp04.pdf (accessed September 2015).
3. Pande R, Leung E, McCullough P, Smith S, Harmston C. Impact of the United kingdom national bowel cancer awareness campaign on colorectal services. Dis Colon Rectum 2014; 57(1): 70–5.
4. Jellema P, van der Windt DA, Bruinvels DJ, et al. Value of symptoms and additional diagnostic tests for colorectal cancer in primary care: systematic review and meta-analysis. BMJ 2010; 340: c1269.
5. Thorne K, Hutchings HA, Elwyn G. The effects of the Two-Week Rule on NHS colorectal cancer diagnostic services: a systematic literature review. BMC Health Serv Res. 2006; 6: 43.
6. National Institute for Health and Care Excellence (NICE). Suspected Cancer: Recognition and Referral (NG12). June 2015, London. Available at: http://www.nice.org.uk/guidance/ng12 (accessed October 2015).
7. Fraser C, Matthew C, Mowat N, Wilson J, Carey F, Steel R. Immunochemical testing in individuals positive for guaiac faecl occult blood test in a screening programme for colorecatal cancer: an observational study. Lancet Oncol 2006; 7: 127–31.
8. Hol L, van Leerdam ME, van Ballegooijen M, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010; 59: 62–8.
9. Dhaliwal A, Zeino Z, Tomkins C, et al. Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply? Frontline Gastroenterol 2015; 6: 14–9.
10. McFarlane M, Chambers S, Malik A, et al. Clinical outcomes at 12 months and risk of inflammatory bowel disease in patients with an intermediate raised fecal calprotectin: a ‘real-world’ view. BMJ Open 2016; 6: e011041.
11. Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagerhol M, Bjarnason I. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 2001; 49: 402–8.
12. Mowat C, Digby J, Strachan J, et al. Faecal haemoglobin and faecal calprotectin as indicators of bowel disease in patients presenting to primary care with bowel symptoms. Gut 2016; 65: 1463–9.
13. Cubiella J, Salve M, Diaz-Ondina M, et al. Diagnostic accuracy of the faecal immunochemical test for colorectal cancer in symptomatic patients: comparison with NICE and SIGN referral criteria. Colorectal Dis 2014; 16: O273–82.
14. Rozen P, Levi Z, Hazazi R, et al. Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms. Aliment Pharmacol Ther 2009; 29: 450–7.
15. Rozen P, Levi Z, Hazazi R, et al. Identification of colorectal adenomas by a quantitative immunochemical faecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed. Aliment Pharmacol Ther 2009; 29: 906–17.
16. Digby J, Fraser CG, Carey FA, et al. Faecal haemoglobin concentration is related to severity of colorectal neoplasia. J Clin Pathol 2013; 66: 415–9.
17. McDonald PJ, Digby J, Innes C, et al. Low faecal haemoglobin concentration potentially rules out significant colorectal disease. Colorectal Dis 2013; 15: e151–9.
18. Hazazi R, Rozen O, Leshno M, et al. Can patients at high risk for significant colorectal neoplasms and having normal quantitative faecal occult blood test postpone elective colonoscopy? Aliment Phramacol Ther 2010; 31: 523–33.
19. Whitehead S, French J, Brookes M, Ford C, Gama R. Between assay variability of faecal calprotectin enzyme-linked immunosorbent assay kits. Ann Clin Biochem 2013; 50: 53–61.